Table 2 Primary and sensitivity analysis for all the studied diseases.

From: Meta-regression of randomized control trials with antithrombotics: weak correlation between net clinical benefit and all cause-mortality

 

Primary outcomes

Sensitivity analysis (only DB)

Sensitivity analysis (only DOAC)

RR (95% CI)

R2 (95% CI)

p Value

RR (95% CI)

R2 (95% CI)

p Value

RR (95% CI)

R2 (95% CI)

p Value

NVAF

NCB

0.66

(0.53; 0.83)

0.41

(0.03; 0.48)

0.0003

0.61

(0.45; 0.83)

0.30

(0.0002, 0.71)

0.08

0.66

[0.47; 0.94)

0.37

(0.007, 0.88)

0.1

ACM

0.78

(0.68; 0.89)

0.89

(0.86; 0.93)

0.79

(061; 1.02)

Acute VTE

NCB

0.73

(0.63; 0.85)

0.30

(0.04; 0.84)

0.003

0.63

(0.48; 0.83)

0.75

(0.006 ; 0.98)

0.0002

0.74

(0.61; 0.90)

0.50

(0.02 ; 0.91)

0.001

ACM

0.98

(088; 1.10)

0.89

(0.75; 1.05)

1.04

(0.94; 1.15)

Thrombop. in medical patients

NCB

0.77

(0.66; 0.90)

0.12

(0.0005; 0.36)

0.08

0.81

(0.67;0.98)

0.11

(0.0003, 0.46)

0.17

0.87

(0.69; 1.09)

0.04

(0.0002, 0.70)

0.59

ACM

0.97

(0.91; 1.03)

0.98

(0.91;1.06)

0.97

(0.88; 1.06)

Thrombop. in major orthopedic surgery

NCB

0.66

(0.58; 0.76)

0.05

(0.0002; 0.23)

0.16

0.65

(0.56; 0.76)

0.07

(0.0003, 0.28)

0.16

0.66

(0.55; 0.79)

0.08

(0.0004, 0.3)

0.15

ACM

0.97

(0.80; 1.16)

0.95

(0.77; 1.17)

0.98

(0.81; 1.22)

Thrombop. in cancer patients

NCB

0.98

(0.67; 1.44)

0.006

(0.0001; 1)

0.84

0.75

(0.56; 1.01)

0.26

(0.0000; 1.00)

0.30

/

/

/

ACM

0.98

(0.92; 1.04)

0.99

(0.93; 1.06)

/

  1. ACM all-cause mortality, CI confidence interval, DB double-blind, DOAC direct oral anticoagulants, NCB net clinical benefit, NVAF non-valvular atrial fibrillation, Thrombop. thromboprophylaxis, RR relative risk, R2 coefficient of determination, VTE venous thromboembolism.
Back to article page